Clinical Trial: Safety and Preliminary Efficacy of Adipose-Derived Stem Cell Secretome in Frailty (VinVital)

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07856602) titled 'Safety and Preliminary Efficacy of Adipose-Derived Stem Cell Secretome in Frailty (VinVital)' on Sept. 28.

Brief Summary: This is a Phase I, open-label, non-randomized clinical trial to evaluate the safety and preliminary efficacy of adipose-derived mesenchymal stem cell secretome capsules (VinVital) in patients with frailty syndrome. A total of 20 participants aged 60 to 75 will receive oral VinVital for 3 months, with an additional 3-month follow-up period (total 6 months). The primary objective is to assess safety based on the frequency and severity of adverse events (AEs) and serious adverse events (SAEs) according to CTCAE v5.0....